On-Demand CME Videos
Strategies to Alleviate the Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Online CME Activity
This activity was recorded at the Winter Clinical Dermatology Conference-Hawaii
CME Satellite Symposium - Strategies to Alleviate the Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Children and Adolescents
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 20, 2023
March 20, 2024
At the completion of this activity, participants should be better able to:
Underline the multidimensional burden of moderate-to-severe atopic dermatitis in children and adolescents
Recall the multidimensional benefits of systemic biologics for the management of moderate-to-severe atopic dermatitis in children and adolescents
Discuss seamless integration of biologics into daily clinical practice through enhanced multidisciplinary care
Alexandra Golant, MD
Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mona Shahriari, MD
Central CT Dermatology
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Consultant: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis, LEO Pharma, Janssen
Speakers’ Bureau or Honoraria: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.